MetaVia (MTVA) Total Non-Current Liabilities (2015 - 2023)
MetaVia's (MTVA) quarterly Total Non-Current Liabilities came in at $3.0 million in Q2 2023, up 95.83% on a QoQ basis from $1.5 million in Q1 2023.
MetaVia (MTVA) Total Non-Current Liabilities (2015 - 2023) Analysis & Trends
MetaVia (MTVA) has 9 years of Total Non-Current Liabilities data on file, last reported at $3.0 million in Q2 2023.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $3.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $3.0 million (changed N/A YoY) and the FY2022 annual result came in at $988000.0, down 55.13% from the prior year.
- Total Non-Current Liabilities rose to $3.0 million in Q2 2023, from $1.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.8 million in Q4 2020 to a low of $988000.0 in Q4 2022.
- A 5-year average of $2.3 million and a median of $2.2 million in 2019 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 506.13% in 2019, down 87.79% in 2019.
- Tracing MTVA's Total Non-Current Liabilities over 5 years: stood at $2.2 million in 2019, then jumped by 73.02% to $3.8 million in 2020, then plunged by 41.51% to $2.2 million in 2021, then plunged by 55.13% to $988000.0 in 2022, then surged by 204.45% to $3.0 million in 2023.
- The last three Total Non-Current Liabilities figures came in at $3.0 million (Q2 2023), $1.5 million (Q1 2023), and $988000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 988,000.00 |
| Dec 31, 2021 | 2.20 Mn |
| Dec 31, 2020 | 3.77 Mn |
| Dec 31, 2019 | 2.18 Mn |
| Sep 30, 2019 | 3.07 Mn |
| Jun 30, 2019 | 2.05 Mn |
| Mar 31, 2019 | 1.71 Mn |
| Dec 31, 2018 | 359,000.00 |
| Sep 30, 2018 | 14.02 Mn |
| Jun 30, 2018 | 13.76 Mn |
| Mar 31, 2018 | 14.02 Mn |
| Dec 31, 2017 | 15.07 Mn |
| Sep 30, 2017 | 16.26 Mn |
| Jun 30, 2017 | 5.27 Mn |
| Mar 31, 2017 | 4.54 Mn |
| Dec 31, 2016 | 4.12 Mn |
| Dec 31, 2015 | 8.92 Mn |